LitAlert ~~ GeneLit.com

    • Update: Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations.
    • [No author given]
    • FORCE. XRAY. 2023 Jan 9.

    •• Identifier: NCT04674306: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 9.)

    • Ideaya to Launch PARG Inhibitor Trial in Homologous Recombination Repair-Deficient Cancers.
    • [No author given]
    • Precision Oncology News. 2023 Jan 9.
    • Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells.
    • Guney Eskiler G, Ozman Z, Haciefendi A, Cansaran-Duman D.
    • Naunyn Schmiedebergs Arch Pharmacol. 2023 Jan 4. doi: 10.1007/s00210-022-02375-4. Epub ahead of print.
    • Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.
    • Nakamura T, Kajihara N, Hama N, Kobayashi T, Otsuka R, Han N, Wada H, Hasegawa Y, Suzuki N, Seino KI.
    • J Gynecol Oncol. 2022 Dec 21. doi: 10.3802/jgo.2023.34.e25. Epub ahead of print.
    • Ideaya Biosciences Files IND With FDA for PARG Inhibitor.
    • [No author goven]
    • Precision Oncology News. 2022 Dec 12.